Alnylam Pharmaceuticals (BSP:A1LN34) Revenue : R$9,071 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Revenue?

Alnylam Pharmaceuticals's revenue for the three months ended in Dec. 2023 was R$2,155 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was R$9,071 Mil. Alnylam Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was R$0.86. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was R$3.56.

During the past 12 months, the average Revenue per Share Growth Rate of Alnylam Pharmaceuticals was 71.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 50.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 75.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 40.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Alnylam Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 112.30% per year. The lowest was -31.50% per year. And the median was 31.90% per year.

Alnylam Pharmaceuticals Revenue Historical Data

The historical data trend for Alnylam Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Revenue Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue

Get a 7-Day Free Trial

901.96

2,535.58

4,774.36

5,441.67

8,958.27

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue	Get a 7-Day Free Trial															1,757.39	1,663.05	1,547.14	3,706.64	2,154.53

Competitive Comparison of Alnylam Pharmaceuticals's Revenue

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Revenue falls into.

Alnylam Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$9,071 Mil.

Alnylam Pharmaceuticals (BSP:A1LN34) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Alnylam Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines